Publications

Our scientific publications in high-quality journals reflect the quality of the innovative research in Entasis’ laboratories.

Newman LM, Kankam M, Nakamura A, Conrad T, Mueller J, O'Donnell J, Osborn BL, Gu K, Saviolakis GA

Thorough QT study to evaluate the effect of zoliflodacin, a novel therapeutic for gonorrhea, on cardiac repolarization in healthy adults

Antimicrobial Agents and Chemotherapy (2021)

Unemo M, Ahlstrand J, Sanchez-Buso, Day M, Aanensen D, Golparian D, Jacobsson S, Cole MJ and European Collaborative Group

High susceptibility to zoliflodacin and conserved target (GyrB) for zoliflodacin among 1209 consecutive clinical Neisseria gonorrhoeae isolates from 25 European countries, 2018

Journal of Antimicrobial Chemotherapy (2021)

Jacobsson S, Kularatne R, Kittiyaowamarn R, Maseko V, Paopang P, Sangprasert P, Sirivongrangson P, Piddock L, Wi T, Alirol E, and Unemo M

High in vitro susceptibility to the first-in-class spiropyrimidinetrione zoliflodacin among consecutive clinical Neisseria gonorrhoeae isolates from Thailand (2018) and South America (2015-2017)

Antimicrobial Agents and Chemotherapy (2019)

Durand-Reville TF, Miller AA, O’Donnell JP, Wu X, Sylvester MA, Guler S, Iyer R, Shapiro AB, Carter NM, Velez-Vega C, Moussa SH, McLeod SM, Chen A, Tanudra AM, Zhang J, Comita-Prevoir J, Romero JA, Huynh H, Ferguson AD, Horanyi PS, Mayclin SJ, Heine HS, Drusano GL, Cummings JE, Slayden RA, and Tommasi RA

Rational design of a new antibiotic class for drug-resistant infections

Nature (2021)

Shapiro AB, Moussa SH, McLeod SM, Durand-Reville T and Miller AA

Durlobactam, a new diazabicyclooctane β-lactamase inhibitor for the treatment of Acinetobacter infections in combination with sulbactam

Frontiers in Microbiology (2021)

Jacobsson S, Golparian D, Oxelbark J, Alirol FF, Gustafsson TN, Brown D, Louie A, Drusano G and Unemo M

Pharmacodynamic evaluation of dosing, bacterial kill, and resistance suppression for zoliflodacin against Neisseria gonorrhoeae in a dynamic hollow fiber infection model

Frontiers in Pharmacology (2021)

O'Donnell J, Maloney K, Steidler M, Morrison R and Isaacs R

A randomized, double-blind, placebo- and positive-controlled crossover study of the effects of durlobactam on cardiac repolarization in healthy subjects

Clinical and Translational Science (2021)

Papp-Wallace KM, Shapiro AB, Becka SA, Zeiser ET, LiPuma JJ, Lane DJ, Panchal RG, Mueller JP, O'Donnell JP, and Miller AA